Balthaser Kevin has filed 58 insider transactions across 1 company since January 2024.
Most recent transaction: a tax payment of 677 shares of Aclaris Therapeutics, Inc. ($ACRS) on March 01, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 1, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | F | Common Stock | 677 | $2.87 | 187,453.0000 | 122,564,741 | 0.36% | 0.00% |
| March 1, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Common Stock | 2375 | $0.00 | 188,130.0000 | 122,564,741 | 1.28% | 0.00% |
| March 1, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Restricted Stock Units | 2375 | $0.00 | 0.0000 | 122,564,741 | 100.00% | 0.00% |
| Feb. 2, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | A | Restricted Stock Units | 99100 | $0.00 | 99,100.0000 | 122,564,741 | 9999.99% | 0.08% |
| Feb. 2, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | A | Employee Stock Option (Right to Buy) | 346800 | $0.00 | 346,800.0000 | 122,564,741 | 9999.99% | 0.28% |
| Feb. 3, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Common Stock | 22025 | $0.00 | 192,204.0000 | 122,564,741 | 12.94% | 0.02% |
| Feb. 3, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | F | Common Stock | 6449 | $3.47 | 185,755.0000 | 122,564,741 | 3.36% | 0.01% |
| Feb. 3, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Restricted Stock Units | 22025 | $0.00 | 66,075.0000 | 122,564,741 | 25.00% | 0.02% |
| Feb. 1, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Common Stock | 14750 | $0.00 | 175,163.0000 | 122,564,741 | 9.20% | 0.01% |
| Feb. 1, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | F | Common Stock | 4984 | $3.51 | 170,179.0000 | 122,564,741 | 2.85% | 0.00% |
| Feb. 1, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Restricted Stock Units | 14750 | $0.00 | 29,500.0000 | 122,564,741 | 33.33% | 0.01% |
| Jan. 2, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | F | Common Stock | 4461 | $2.88 | 160,413.0000 | 122,564,741 | 2.71% | 0.00% |
| Jan. 1, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | F | Common Stock | 2250 | $3.01 | 151,674.0000 | 122,564,741 | 1.46% | 0.00% |
| Jan. 1, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Common Stock | 7500 | $0.00 | 153,924.0000 | 122,564,741 | 5.12% | 0.01% |
| Dec. 31, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | F | Common Stock | 19934 | $3.01 | 146,424.0000 | 122,619,311 | 11.98% | 0.02% |
| Dec. 31, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Common Stock | 73750 | $0.00 | 166,358.0000 | 122,619,311 | 79.64% | 0.06% |
| Jan. 2, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Restricted Stock Units | 13200 | $0.00 | 13,600.0000 | 122,564,741 | 49.25% | 0.01% |
| Jan. 1, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Restricted Stock Units | 7500 | $0.00 | 7,500.0000 | 122,564,741 | 50.00% | 0.01% |
| Dec. 31, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Restricted Stock Units | 73750 | $0.00 | 0.0000 | 122,619,311 | 100.00% | 0.06% |
| Jan. 2, 2026 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Common Stock | 13200 | $0.00 | 164,874.0000 | 122,564,741 | 8.70% | 0.01% |
| March 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Common Stock | 2375 | $0.00 | 93,335.0000 | 77,296,665 | 2.61% | 0.00% |
| March 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Restricted Stock Units | 2375 | $0.00 | 2,375.0000 | 77,296,665 | 50.00% | 0.00% |
| March 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Restricted Stock Units | 1100 | $0.00 | 0.0000 | 77,296,665 | 100.00% | 0.00% |
| March 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Common Stock | 1100 | $0.00 | 90,960.0000 | 77,296,665 | 1.22% | 0.00% |
| March 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | F | Common Stock | 727 | $1.99 | 92,608.0000 | 77,296,665 | 0.78% | 0.00% |
| Feb. 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Restricted Stock Units | 14750 | $0.00 | 44,250.0000 | 77,296,665 | 25.00% | 0.02% |
| Feb. 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Common Stock | 14750 | $0.00 | 95,676.0000 | 77,296,665 | 18.23% | 0.02% |
| Feb. 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | F | Common Stock | 5816 | $2.48 | 89,860.0000 | 77,296,665 | 6.08% | 0.01% |
| Feb. 3, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | A | Restricted Stock Units | 88100 | $0.00 | 88,100.0000 | 77,296,665 | 9999.99% | 0.11% |
| Feb. 3, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | A | Employee Stock Option (Right to Buy) | 308200 | $0.00 | 308,200.0000 | 77,296,665 | 9999.99% | 0.40% |
| Jan. 2, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Common Stock | 13200 | $0.00 | 85,985.0000 | 77,296,665 | 18.14% | 0.02% |
| Dec. 31, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Common Stock | 73750 | $0.00 | 98,447.0000 | 71,381,731 | 298.62% | 0.10% |
| Jan. 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Common Stock | 7500 | $0.00 | 75,215.0000 | 77,296,665 | 11.08% | 0.01% |
| Jan. 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | F | Common Stock | 2430 | $2.48 | 72,785.0000 | 77,296,665 | 3.23% | 0.00% |
| Jan. 2, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | F | Common Stock | 5059 | $2.48 | 80,926.0000 | 77,296,665 | 5.88% | 0.01% |
| Jan. 2, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Restricted Stock Units | 13200 | $0.00 | 26,800.0000 | 77,296,665 | 33.00% | 0.02% |
| Jan. 2, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | A | Restricted Stock Units | 40000 | $0.00 | 40,000.0000 | 77,296,665 | 9999.99% | 0.05% |
| Jan. 1, 2025 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Restricted Stock Units | 7500 | $0.00 | 15,000.0000 | 77,296,665 | 33.33% | 0.01% |
| Dec. 31, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Restricted Stock Units | 73750 | $0.00 | 73,750.0000 | 71,381,731 | 50.00% | 0.10% |
| Dec. 31, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | F | Common Stock | 30732 | $2.48 | 67,715.0000 | 71,381,731 | 31.22% | 0.04% |
| Sept. 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Restricted Stock Units | 1000 | $0.00 | 0.0000 | 71,291,400 | 100.00% | 0.00% |
| Sept. 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | F | Common Stock | 286 | $1.18 | 24,697.0000 | 71,291,400 | 1.14% | 0.00% |
| Sept. 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Common Stock | 1000 | $0.00 | 24,983.0000 | 71,291,400 | 4.17% | 0.00% |
| March 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Common Stock | 1100 | $0.00 | 21,525.0000 | 69,808,855 | 5.39% | 0.00% |
| March 2, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Restricted Stock Units | 1500 | $0.00 | 0.0000 | 69,808,855 | 100.00% | 0.00% |
| March 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Restricted Stock Units | 1100 | $0.00 | 1,100.0000 | 69,808,855 | 50.00% | 0.00% |
| March 2, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | F | Common Stock | 427 | $1.24 | 23,983.0000 | 69,808,855 | 1.75% | 0.00% |
| March 2, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Common Stock | 1500 | $0.00 | 24,410.0000 | 69,808,855 | 6.55% | 0.00% |
| March 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | F | Common Stock | 677 | $1.24 | 22,910.0000 | 69,808,855 | 2.87% | 0.00% |
| March 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Common Stock | 2375 | $0.00 | 23,587.0000 | 69,808,855 | 11.20% | 0.00% |
| March 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | F | Common Stock | 313 | $1.24 | 21,212.0000 | 69,808,855 | 1.45% | 0.00% |
| March 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Restricted Stock Units | 2375 | $0.00 | 4,750.0000 | 69,808,855 | 33.33% | 0.00% |
| Feb. 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | A | Restricted Stock Units | 147500 | $0.00 | 147,500.0000 | 69,808,855 | 9999.99% | 0.21% |
| Feb. 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | A | Restricted Stock Units | 59000 | $0.00 | 59,000.0000 | 69,808,855 | 9999.99% | 0.08% |
| Feb. 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | A | Employee Stock Option (Right to Buy) | 206500 | $0.00 | 206,500.0000 | 69,808,855 | 9999.99% | 0.30% |
| Jan. 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Restricted Stock Units | 7500 | $0.00 | 22,500.0000 | 69,808,855 | 25.00% | 0.01% |
| Jan. 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | F | Common Stock | 2536 | $1.05 | 20,425.0000 | 69,808,855 | 11.04% | 0.00% |
| Jan. 1, 2024 | Aclaris Therapeutics, Inc. | $ACRS | Balthaser Kevin | Chief Financial Officer | M | Common Stock | 7500 | $0.00 | 22,961.0000 | 69,808,855 | 48.51% | 0.01% |